Zacks Investment ResearchThu, 14 May 2026 15:20:56 GMTCan Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?LLY-0.89%
The Motley FoolThu, 14 May 2026 09:05:00 GMTShould Eli Lilly Investors Worry About Its Newest Rival -- From Within?LLY-0.89%
Schwab NetworkWed, 13 May 2026 19:30:05 GMTCharts to Watch: SPX All-Time High, CIFR & LLY BreakoutsLLY-0.89%
BenzingaWed, 13 May 2026 18:43:40 GMTThis Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: AnalystLLY-0.89%
Zacks Investment ResearchWed, 13 May 2026 16:52:28 GMTLilly Bets on Next-Generation Obesity Drugs to Stay AheadLLY-0.89%
BenzingaWed, 13 May 2026 15:33:21 GMTEli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight LossLLY-0.89%
24/7 Wall StreetTue, 12 May 2026 15:25:12 GMTEli Lilly Price Prediction: This Is Where The Stock Will End This YearLLY-0.89%
24/7 Wall StreetTue, 12 May 2026 11:40:31 GMTLilly Bounces Into ‘Sell in May' Territory as Pricing Pressures LoomLLY-0.89%
Zacks Investment ResearchMon, 11 May 2026 14:51:22 GMTWhy Eli Lilly (LLY) is a Top Momentum Stock for the Long-TermLLY-0.89%
24/7 Wall StreetMon, 11 May 2026 13:05:08 GMTPfizer vs Eli Lilly: Different Bets on Pharma M&ALLY-0.89%
Schwab NetworkSun, 10 May 2026 18:30:53 GMTAI, Obesity Drugs, and Diagnostics Fuel Healthcare GrowthLLY-0.89%
Seeking AlphaSun, 10 May 2026 11:11:38 GMTEli Lilly: 'Strong Buy' Raised Revenue Guidance By $2 Billion For 2026 And Label ExpansionsLLY-0.89%
Investors Business DailyFri, 08 May 2026 12:00:30 GMTEli Lilly's Retatrutide Is So Hot, The Unlaunched Weight-Loss Drug Is Already Getting Knocked OffLLY-0.89%
Investors Business DailyThu, 07 May 2026 20:20:46 GMTHow This Eli Lilly-Tied IPO Stock Fared In Its First QuarterLLY-0.89%
Investors Business DailyThu, 07 May 2026 16:10:34 GMTRetatrutide Black Market: Why Consumers Will Do Anything To Get Eli Lilly's New GLPLLY-0.89%
Zacks Investment ResearchThu, 07 May 2026 14:45:30 GMTHere's Why Eli Lilly (LLY) is a Strong Growth StockLLY-0.89%
MarketBeatThu, 07 May 2026 14:05:28 GMTWhat the FDA's Latest Proposal Means for Lilly, Novo, and HimsLLY-0.89%
WSJThu, 07 May 2026 09:30:00 GMTHeard on the Street: The fastest-growing part of the weight-loss market—and perhaps the most underappreciated driver for both Novo Nordisk and Lilly—is outside the U.S.LLY-0.89%
